Gilead Sciences, Inc. (FRA:GIS)

Market Cap	122.11B
Revenue (ttm)	26.59B
Net Income (ttm)	5.52B
Shares Out	n/a
EPS (ttm)	4.38
PE Ratio	22.13
Forward PE	13.69
Dividend	2.84 (2.89%)
Ex-Dividend Date	Jun 13, 2025

Volume	100
Average Volume	112
Open	99.27
Previous Close	100.00
Day's Range	98.26 - 99.27
52-Week Range	66.63 - 111.04
Beta	n/a
RSI	61.58
Earnings Date	Aug 1, 2025

About MorphoSys AG

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GIS

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.